biostudies-literatureKaisaki PJOxford Experimental Cancer Medicine CentreCancer Research UKTechnology Strategy BoardNational Institute for Health Research (NIHR)Wellcome Truste0162809https://www.ebi.ac.uk/biostudies/studies/S-EPMC5023174biostudies-literatureUnknown11(9)Use of circulating tumour DNA (ctDNA) as a liquid biopsy has been proposed for potential identification and monitoring of solid tumours. We investigate a next-generation sequencing approach for mutation detection in ctDNA in two related studies using a targeted panel. The first study was retrospective, using blood samples taken from melanoma patients at diverse timepoints before or after treatment, aiming to evaluate correlation between mutations identified in biopsy and ctDNA, and to acquire a first impression of influencing factors. We found good concordance between ctDNA and tumour mutations of melanoma patients when blood samples were collected within one year of biopsy or before treatment. In contrast, when ctDNA was sequenced after targeted treatment in melanoma, mutations were no loPloS oneTargeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for Diagnosis.PMC50231748466090532/Z/09/ZTP No: 10809-62174Taylor JCCutts ATalbot DCPage SCamps CSchuh AHenderson SVavoulis DKarydis IPopitsch NKaisaki PJGupta APentony MMWilson GKaur KMiddleton MRfalseTargeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for Diagnosis.Use of circulating tumour DNA (ctDNA) as a liquid biopsy has been proposed for potential identification and monitoring of solid tumours. We investigate a next-generation sequencing approach for mutation detection in ctDNA in two related studies using a targeted panel. The first study was retrospective, using blood samples taken from melanoma patients at diverse timepoints before or after treatment, aiming to evaluate correlation between mutations identified in biopsy and ctDNA, and to acquire a first impression of influencing factors. We found good concordance between ctDNA and tumour mutations of melanoma patients when blood samples were collected within one year of biopsy or before treatment. In contrast, when ctDNA was sequenced after targeted treatment in melanoma, mutations were no lo2016-01-01T00:00:00Z20162026-05-04T18:57:22.839Z2019-03-26T22:48:09ZS-EPMC50231742762627810.1371/journal.pone.0162809